Syros Pharmaceuticals Inc. (SYRS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Syros Pharmaceuticals Inc... (SYRS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.24

0.00 (1.01%)

At close: Jan 15, 2025, 3:59 PM

0.22

-6.59%

After-hours Jan 15, 2025, 05:04 PM EST

undefined% (undefined)

Bid	0.22
Market Cap	6.39M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.07
PE Ratio (ttm)	-0.08
Forward PE	n/a
Analyst	Hold

Ask	0.24
Volume	1,669,652
Avg. Volume (20D)	9,687,409
Open	0.23
Previous Close	0.24
Day's Range	0.21 - 0.25
52-Week Range	0.18 - 7.96
Beta	undefined

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 30, 2016

Employees 68

Stock Exchange NASDAQ

Ticker Symbol SYRS

Website https://www.syros.com

Analyst Forecast

According to 5 analyst ratings, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 1159.45% from the latest price.

Buy 20.00%

Hold 80.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Syros Pharmaceuticals Inc. is scheduled to release its earnings on Mar 26, 2025, before market opens.
Analysts project revenue of $450.00K, reflecting a 16.28% YoY growth and earnings per share of -0.74, making a -66.06% decrease YoY.

Why Price Moved

1 month ago · Source

+39.24%

Syros Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

1 month ago · Source

-23.33%

Syros Pharmaceuticals shares are trading lower after the company announced it gave notice to QIAGEN Manchester of its election to terminate the Master Collaboration Agreement.

News

2 months ago · zacks.com

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

2 months ago · benzinga.com

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.

2 months ago · businesswire.com

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies...

2 months ago · seekingalpha.com

Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript

Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications C...

2 months ago · businesswire.com

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancie...

2 months ago · businesswire.com

Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024